|
Mr. Kollins joined OXiGENE in March 2007. He brings to OXiGENE nearly 20 years of experience in the biopharmaceutical and biotechnology industry in business development new product development and strategic marketing roles.
Since February 2005 John has served as an independent consultant and advisor to public and private biopharmaceutical companies as well as GRT Capital LLC’s GRT Health Care LP investment fund where he worked closely with the fund’s portfolio manager in evaluating biopharmaceutical and other health care investment opportunities. From 2004 to 2005 John served as Chief Business Officer of CovX and currently serves as Chairman of the company’s advisory board. From 2003 to 2004 he served as Vice President of Business Development at Renovis Inc. where he played a principal role in establishing the company’s first industrial research and development partnerships with Genentech and Merck. From 2000 to 2002 John served as Vice President Business Development at SurroMed where he was instrumental in establishing the company’s first revenue-generating industrial collaborations with pharmaceutical companies.
John began his career in the biopharmaceutical industry in 1989 as a Product Manager at Immunex Corporation where he contributed to the commercial launch of LEUKINE® the company’s first commercial product and served on the development teams for ENBREL® and other development-stage biopharmaceutical candidates. He subsequently served in new product commercialization and business development roles of increasing responsibility at Athena Neurosciences and Elan Pharmaceuticals. John earned a BSE degree (mechanical engineering and materials science) magna cum laude from Duke University and an MBA with honors from the University of Virginia’s Darden School. | 